Skip Navigation



Bioinformatics Advance Access published online on December 8, 2005
Bioinformatics, doi:10.1093/bioinformatics/bti824
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
22/4/466    most recent
bti824v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Li, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received July 14, 2005
Revised November 7, 2005
Accepted December 6, 2005

Article

Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information

Lexin Li 1 *

1 Department of Statistics, North Carolina State University, Raleigh, NC 27695, USA

* To whom correspondence should be addressed.
Lexin Li, E-mail: li{at}stat.ncsu.edu


  Abstract

Motivation: It is important to predict the outcome of patients with diffuse large-B-cell lymphoma after chemotherapy, since the survival rate after treatment of this common lymphoma disease is less than 50 percent. Both clinically-based outcome predictors and the gene expression-based molecular factors have been proposed independently in disease prognosis. However combining the high-dimensional genomic data and the clinically relevant information to predict disease outcome is challenging.

Results: We describe an integrated clinicogenomic modeling approach that combines gene expression profiles and the clinically-based International Prognostic Index (IPI) for personalized prediction in disease outcome. Dimension reduction methods are proposed to produce linear combinations of gene expressions, while taking into account clinical IPI information. The extracted summary measures capture all the regression information of the censored survival phenotype given both genomic and clinical data, and are employed as covariates in the subsequent survival model formulation. A case study of diffuse large-B-cell lymphoma data, as well as Monte Carlo simulations, both demonstrate that the proposed integrative modeling improves the prediction accuracy, delivering predictions more accurate than those achieved by using either clinical data or molecular predictors alone.

Availability: R programs are available at http://www4.stat.ncsu.edu/~li/survipi/.

Supplementary Information: http://www4.stat.ncsu.edu/~li/survipi/bioinfo-supp.pdf.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
J. Beane, P. Sebastiani, T. H. Whitfield, K. Steiling, Y.-M. Dumas, M. E. Lenburg, and A. Spira
A Prediction Model for Lung Cancer Diagnosis that Integrates Genomic and Clinical Features
Cancer Prevention Research, June 1, 2008; 1(1): 56 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert
Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome
Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.